Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for Q3 2024 in Phase 2 trial...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Phoenix ,Arizona ,United States ,Black Diamond ,American ,Mark Velleca ,Mario Corso ,Diamond Therapeutics Inc ,Drug Administration ,Company Masterkey ,Nasdaq ,European Organization For Research ,American Association For Cancer Research ,Ivy Brain Tumor Center ,Development Expenses ,Exchange Commission ,National Cancer Institute ,Diamond Therapeutics ,Chief Executive Officer ,Upcoming Milestones ,European Organization ,Cancer Research ,Molecular Targets ,Cancer Therapeutics ,American Association ,Administrative Expenses ,Private Securities Litigation Reform Act ,Annual Report ,United States Securities ,Consolidated Balance Sheet Data ,Investor Relations ,